

6-MP = 6-mercaptopurine

HPV = human papillomavirus

HAV = hepatitis A virus

ACG GUIDELINE Highlights

Preventive Care in Inflammatory Bowel Disease

Concept and Content: Erica Duh, MD | Reviewer: Freddy Caldera, DO, MS, PhD, FACG

accinations		PATIENT GROUP	INTERVAL			
X		19-49 years	If PCV naïve: PCV 21 or PCV 20 Examples of complete			
	PCV 21 or PCV 20	(immunocompromised)	If incomplete PCV: PCV 13		PCV 13 ≥1 y → PCV 21 or PCV 20	pneumonia vaccine regimens:
		50-64 years	If PCV naïve	: PCV	21 or PCV 20	PCV 13 and 2 dosesof PPSV 23PCV 15 and PPSV 23
		50 0 1 years	If incomplet	e PCV	PCV 13 + PPSV23 ≥5 y → PCV 21 or PCV 20	
		≥65 years				• PCV 20 or PCV 21
			If incomplete PCV: ≥ 5 yrs since last PCV → PCV 21 or PCV 20			
	Zoster	≥19 years	2-dose inactive recombinant herpes zoster vaccine.0-1 month apart in immunocompromised; 2-6 months in all others.			
	COVID-19	All adults	Follow recommendations from Centers for Disease Control and Prevention.			
	Rotavirus vaccine	Infants exposed to biologics in-utero	Administer rotavirus vaccine to infants exposed to biologics in utero.			
	Influenza	All adults	 ≥65 years → recombinant, adjuvant or high dose influenza vaccine. Adults 19-64 years who are liver transplant recipients OR on anti-TNF monotherapy → high dose influenza vaccine All other adults 19-64 → standard dose influenza vaccine 			
	RSV	≥50 years	 All adults ≥75 years Adults 50-74 years with certain medical conditions (including patients with IBD and liver transplant recipients) 			
	Tdap, HAV, HPV, Meningococcal	All adults	Administer according to Advisory Committee on Immunization Practice Recommendations			
	Hepatitis B	All adults	 Evaluate for seroprotection status (Check for HbsAb > 10 mlU/mL). If negative and previously immunized → provide challenge dose Not immune → provide Hepatitis B vaccine 2 or 3 dose series. 			
	Do NOT check serologic titers to evaluate for immunity to MMR or varicella.				Provide age-appropriate vaccines before initiation modifying therapies when possible.	of immune-
Cancer Prevention		PATIENT GROUP		INTER	RVAL	
	Cervical Cancer Screening	modifying therapy		 Within a year of onset of sexual activity Continue annually If <30, continue for 3 consecutive years before increasing to every 3 years Assure receipt of HPV vaccine series 		
	Skin Check			 Annual screening for melanoma (independent of use of biologic therapy) Annual screening for NMSC (on immune-modifying therapies ex: 6-MP, azathioprine, methotrexate, JAK inhibitors, or S1P receptor modulators) 		
ther Health		PATIENT GROUP		INTERVAL		
Maintenance	Osteoporosis	Adults with IBD and conventional risk factors for abnormal bone mineral density			At time of diagnosis and periodically after dia	gnosis
	Smoking	IBD patients who smoke			Counseling for smoking cessation	
	Mental health	All adults			Screen for depression and anxiety at baseline and annually. Refer for counseling/therapy.	

Francis A. Farraye, MD, MSc, MACG; Gil Y. Melmed, MD, MPH, FACG; Gary R. Lichtenstein, MD, FACG; Edward Barnes, MD, MPH, FACG; Berkeley N. Limketkai, MD, PhD, FACG; Freddy Caldera, DO, PhD, FACG; Sunanda Kane, MD, MSPH, MACG *The American Journal of Gastroenterology* DOI: 10.14309/ajg.0000000000003541

NMSC = non-melanoma squamous cell cancer

IBD= inflammatory bowel disease

JAK = janus kinase



S1P = sphingosine-1-phosphate

TNF = tumor necrosis factor

TDAP = tetanus, diptheria, and pertussis

PCV = pneumococcal conjugate vaccine

RSV= respiratory syncytial virus

PPSV = pneumococcal polysaccharid vaccine